Skip to content

Bicara Therapeutics

US · BCAX #3193 by market cap Listed 2024
8.44 -0.68 -7.46%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 9.00 -1.32%
After-hours 8.44 0.00%
30.407.938.442026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on BCAX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -56.6% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 14.9% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -30.9% Better than 12%
Return on invested capital -33.8% Better than 9%
Momentum D-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -64.7% Better than 2%
6-month return -61.1% Better than 4%
12-month return (ex latest month) -2.4% Better than 30%
Distance below 52-week high 72.8% Better than 5%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 14.6x Better than 96%
Debt to assets 0.4% Better than 96%
Interest coverage -336.9x Better than 3%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 87.5% Better than 69%
Upside to average target 274.8% Better than 97%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -15.77%
1M -54.01%
3M -65.40%
6M -58.69%
YTD -49.85%
1Y -47.84%

Key statistics

Price & volume

Prev close
9.12
Open
8.83
Day range
8.43 - 9.14
Avg price
8.66
Volume
814.51K
Turnover
7.06M
Amplitude
7.79%
52-week range
7.87 - 30.99

Valuation

P/E
-3.35
P/E (TTM)
-2.44
P/B
1.37
EPS
-2.52
Net profit
-167.30M
Net assets
409.41M

Share structure

Market cap
560.31M
Float cap
310.27M
Shares out
66.39M
Float shares
36.76M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2024-09-13
52-week range 2% of range
7.87 30.99

72.8% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+7.94M net over the window

Short interest

Shares short
9.86M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Bicara Therapeutics (BCAX)?

Bicara Therapeutics last traded at 8.44. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Bicara Therapeutics's market cap?

About 560.31M.

What is the P/E ratio of Bicara Therapeutics?

The trailing twelve-month P/E is -2.44. The Valuation tab shows it against the stock's own five-year range.

Does Bicara Therapeutics pay a dividend?

Bicara Therapeutics does not currently pay a regular dividend.

Is Bicara Therapeutics a buy according to analysts?

The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 31.63, which implies 274.8% upside from the current price. This is not investment advice.

What is Bicara Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Bicara Therapeutics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:30:00 · For reference only, not investment advice and not tailored to your situation.

Bicara Therapeutics discussion 0 comments

Add a comment